Role of polymorphic CYP2E1 and CYP2D6 genes in NNK-induced chromosome aberrations in cultured human lymphocytes

Pharmacogenetics

Volumn 10, Issue 3, 2000, Pages 239-249

  Abdel Rahman, Sherif Z ^a,c   Salama, Salama A ^b   Au, William W ^a   Hamada, Farid A ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Al Azhar University   (Egypt)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cancer; CYP2D6; CYP2E1; Cytochrome p450; FISH; Genetic susceptibility; Metabolism; NNK; Polymorphism; Smoking

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; DEBRISOQUINE 4 HYDROXYLASE; DIETHYLDITHIOCARBAMIC ACID; DIMETHYLNITROSAMINE DEMETHYLASE; ENZYME INHIBITOR; NITROSAMINE; QUINIDINE;

ADULT; ARTICLE; BLOOD CULTURE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTOXICITY; GENOTYPE; HUMAN; HUMAN CELL; LUNG CANCER; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; METABOLIC ACTIVATION; PRIORITY JOURNAL; SMOKING;

NICOTIANA TABACUM;

EID: 0034007880     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200004000-00005     Document Type: Article

References (78)

1. Abdel-Rahman SZ, Nouraldeen AM, Ahmed AE. Molecular interaction of [2,3-14C] acrylonitrile with DNA in gastric tissue of rat. J Biochem Toxicol 1994; 9:191-198.
2. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa MH, Au WW. The CYP2D6 extensive metabolizer genotype increases the risk for bladder cancer. Cancer Lett 1997; 119:115-122.
3. Abdel-Rahman SZ. El-Zein RA, Zwischenberger JB, Au WW. Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers. Mutat Res 1998; 398:43-54.
4. Agúndez JAG, Martinez C, Lardero JM, Ledesma MC, Ramos JM, Martin R, et al. Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994; 55:10-14.
5. Alaoui-Jamali MA, Castonguay A, Schuller HM. In-vitro genotoxicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone activated by hamster maternal and fetal tissues. Carcinogenesis 1988; 9:2319-2324.
6. Albertini RJ, Nicklas JA, O'Neill PJ. Future research directions for evaluating human genetic and cancer risk from environmental exposures. Environ Health Perspect 1996; 104 (Suppl 3):503-510.
7. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996; 17:1923-27.
8. Au WW, Walker DM, Ward JB, Whorton E, Legator MS, Singh V. Factors contributing to chromosome damage in lymphocytes of cigarette smokers. Mutat Res 1991; 260:137-144.
9. Au WW, Cajas-Salazar N, Salama S. Factors contributing to discrepancies in population monitoring studies. Mutat Res 1998; 400:467-478.
10. Bourrié M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol ExpTher 1996; 277:321-332.
11. Brembilla-Perrot B, Alsagheer S, Jacquemin L, Beurrier D, Relournay G, Grentzinger A. Influence of anti-arrhythmia agents on heart rate variability. Ann Cardiol Angeiol (Paris) 1997; 46:129-134.
12. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase & cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56:3915-3925.
13. Brunnemann KD. Analytical studies on N-nitrosamines in tobacco and tobacco smoke. In: American Health Foundation, editors. Chemical studies in tobacco smoke. Valhalla, NY, USA: National Institute of Health; 1993, pp. 71-113.
14. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphism to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991; 2:4-19.
15. Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M. CYP2D6 mRNA expression in circulating peripheral mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol 1996; 91:149-159.
16. Chen C, Cook LS, Li XY, Hallagan S, Madeline MM, Daling JR, Weiss NS. CYP2D6 genotype and the incidence of anal and valvular cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:317-321.
17. Chinegwundoh FI, Kaisary AV. Polymorphism and smoking in bladder carcinogenesis. Br J Urol 1996; 77:672-675.
18. Conforti-Froes N, El-Zein RA, Abdel-Rahman SZ, Zwischenberger JB, Au WW. Predisposing genes and increased chromosome aberrations in lung cancer cigarette smokers. Mutt Res 1997; 379:53-59.
19. Crespi CL, Penman BW, Gelboin HV, Gonzalez, FJ. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991; 12:1197-1201.
20. Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JT, et al. Comparison of substrate metabolism by wild-type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics, 1995; 5:234-243.
21. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
22. Rastmond DA, Rupa DS, Hasegawa LS. Detection of hyperdiploidy and chromosome breakage in interphase human lymphocytes following exposure to benzene metabolite hydroquinone using multicolor fluorescence in-situ hybridization with DNA probes. Mutat Res 1994; 322:9-20.
23. El-Zein RA, Zwischenberger JB, Wood TG, Abdel-Rahman SZ, Breckelbaum C, Au WW. Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 1997a; 381:189-200.
24. El-Zein RA, Zwischenberger JB, Abdel-Rahman SZ, Sankar AB, Au WW. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett 1997b; 112:71-78.
25. El-Zein R. Conforti-Froes N, Au WW. Interactions between genetic predisposition and environmental toxicants for development of lung cancer. Environ Mol Mutagen 1997c; 30:196-204.
26. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48:943-950.
27. Hawksworth GM. Advantages and disadvantages of using human cells for pharmacological and toxicological studies. Hum Exp Toxicol 1994; 13:568-573.
28. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 1991; 110:559-565.
29. Hecht SS. Metabolic activation and detoxification of tobacco-specific nitrosamines - a model for cancer prevention strategies. Drug Met Rev 1994; 26:373-390.
30. Hecht SS. Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Crit Rev Toxicol 1996; 26:163-181.
31. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Cheni Res Toxicol 1998; 11:559-603.
32. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of in-vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998; 26:207-215.
33. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3:19-27.
34. Hoffmann D, Rivenson A, Murphy SE, Chung F-L, Amin S, Hecht SS. Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived nitrosamines. J Smoking Rel Disord 1993; 4:165-190.
35. Hoffmann D, Rivenson A, Hecht SS. The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Crit Rev Toxicol 1996; 26:199-211.
36. Hong JY, Wang ZY, Smith TJ, Zhou S, Shi S, Pan J, Yang CS. Inhibitory effects of diallyl sulfide on the metabolism and tumorigenicity of the tobacco-specific carcinogen 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mouse lung. Carcinogenesis 1992; 13:901-914.
37. IARC. Tobacco smoking. IARC monographs for the evaluation of the carcinogenic risk of chemicals to humans. Lyon, France: IARC; 1986, pp. 312-314.
38. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer U. Multiple mutations of the human cylochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrizoquine. J Biol Chem 1990; 265:17209-17214.
39. Kaina B. Critical steps in alkylation-induced aberration formation. Mutat Res 1998; 404:119-124.
40. 6-alkylguanine and N-alkylpurines to the formation of sister chromatic! exchanges, chromosomal aberrations, and gene mutations: new insights gained from studies of genetically engineered mammalian cell lines. Environ Mol Mutagen 1993; 22:283-292.
41. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992; 52:6712-6715.
42. Krynetskii E, Kovaleva I. Study of transcription of human CYPIID6 gene by polymerase chain reaction. Mol Biol (Mosk) 1992; 26:943-948.
43. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, Lau AF. (1998) Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998; 58:4858-4863.
44. Lilly LJ. Investigations in vitro and in vivo, of the effects of disulfiram (antabuse) on human lymphocyte chromosomes. Toxicology 1975; 4:331-340.
45. Liu LL, Alaoui-Jamali MA, El Alami N, Castonguay A. Metabolism and DNA single strand breaks induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its analogues in primary culture of rat hepatocytes. Cancer Res 1990; 50:1810-1816.
46. London SJ, Daly AK, Leathart JB, Navidi WC, Carpenter CC, Idle JR. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997; 18:1203-1214.
47. Marie JP, Simonin G, Legrand O, Delmer A, Faussat AM, Lewis AD, et al. Glulathione S-transferases Pi, alpha, mu and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 1995; 9:1742-1747.
48. Morse MA. Inhibition of NNK-induced lung tumorigenesis by modulators of NNK activation. Exp Lung Res 1998; 24:595-604.
49. Nebert D. Ingelman-Sundberg M, Daly AK. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes. their functional importance and nomenclature issues. Drug Met Rev 1999; 31:467-487.
50. Norppa H. Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Environ Health Perspect 1997; 105 (Suppl 4):829-835.
51. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, Yasumoto K. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 1997; 17:583-587.
52. Padma PR, Amonkar AJ, Bhide SV. Mutagenic and cytogenetic studies of N-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Lett 1989; 46:173-180.
53. Patten CJ, Smith TJ, Murphy SE, Wang MH, Lee J, Tynes RE, et al. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch Biochem Biophys 1996; 333:127-138.
54. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 1993; 28-39.
55. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylander R, et al. Genetic polymorphism of cylochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319:207-211.
56. 6-methylguanine. Cancer Res 1993; 53:2780.
57. Raucy JL, Curley G. Carpenter SP. Use of lymphocytes for assessing ethanol-mediated alterations in the expression of hepatic cytochrome P450 2E1. Alcohol Clin Exp Res 1995; 19:1369-1375.
58. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997; 25:1429-1435.
59. Roots L, Brockmöller J, Drakoulis N, Loddenkemper R. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class mu and arylamine N-acetyltransferase in lung cancer patients. J Clin Invest 1992; 70:307-319.
60. Rostami-Hodjegan A, Leonard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Phannacogenetics 1998; 8:227-238.
61. Salama AS, Serrana M, Au WW. Biomonitoring using accessible human cells for exposure and health risk assessment. Mutat Res 1999; 436:99-112.
62. Salama AS. Abdel-Rahman SZ, Sierra-Torres CH, Hamada FA, Au WW. Role of polymorphic GSTM1 and CSTT1 genotypes on NNK-induced genotoxicity Pharmacogenetics 1999; 9:735-743.
63. Shaw GL, Weiffenbach B, Falk RT, Frame JN, Issaq HJ, Moir DT, Caporaso N. Frequency of the variant allele CYP2D6 (C) among North American Caucasian lung cancer patients and controls. Lung Cancer 1997; 17:61-68.
64. Shaw GL, Falk RT, Frame JN, Weiffenbach B, Nesbitt JC, Pass HI, et al. Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7:215-219.
65. Smith TJ, Guo Z, Gonzalez FJ, Guengerich PF, Stoner G, Yang CS. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochrome P-450 expressed in hepatoma cells. Cancer Res 1992; 52:1757-1763.
66. Spiegelhalder B, Bartsch H. Tobacco-specific nitrosamines. Eur J Cancer Prev 1996; 5 (Suppl 1):33-38.
67. Spurr N, Cough AC, Smith D, Wolf R. Genetic analysis of cytochrome P450 system. Methods Enzymol 1991; 206:149-166.
68. Szarka CE, Pfeiffer GR, Hum ST, Everley LC, Balshem AM, Moore DF, et al. Glutathione S-transferase activity and glutathione S-transferase mu expression in subjects with risk for colorectal cancer. Cancer Res 1995; 55:2789-2793.
69. Travis WD, Travis LB, Devesa SS. Lung cancer [published erratum appears in Cancer (Phila) 1995; 75:2979]. Cancer 1995; 74:191-205.
70. Uematsu F, Kikuchi H, Motomiya M, Abe T. Sagami I, Ohmachi T, et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991; 82:254-256.
71. United States Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General, Rockville, MD: United States Department of Health and Human Services; 1989, pp. 89-8411.
72. Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, et al. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics, 1998; 8:433-439.
73. Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, Spitz MR. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev 1998; 7:13-18.
74. Wynder EL, Hoffman D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res 1994; 54:5284-5295.
75. Yamazaki H, Oda Y, Funae Y, Imaoka S, Inui Y, Guengerich FP, Shimada T. Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 1992a; 13:979-985.
76. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cylochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992b; 13:1789-1794.
77. Yoo JS., Ishizaki H, Yang CS. Roles of cytochrome P450IIE1 in the dealkylation and denitrosation of N-nitrosodimethylamine and N-nitrosodiethylamine in rat liver microsomes. Carcinogenesis 1990; 11:2239-2243.
78. Zimonjic D, Popescu NC, Dipaolo JA. Induction of sister chromatid exchanges by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human and hamster cells. Carcinogenesis 1989; 10:753-755.